Show simple item record

dc.contributor.authorFlynn, Men_US
dc.contributor.authorYoung, Ken_US
dc.contributor.authorCunningham, Den_US
dc.contributor.authorStarling, Nen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-02-25T16:09:47Z
dc.date.issued2018en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30034550en_US
dc.identifier10.1177_1758835918786228en_US
dc.identifier.citationTher Adv Med Oncol, 2018, 10 pp. 1758835918786228 - ?en_US
dc.identifier.issn1758-8340en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3086
dc.identifier.doi10.1177/1758835918786228en_US
dc.description.abstractImprovements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing unexpected durable responses in an expanding list of advanced disease indications. Although OG cancers have traditionally been considered to be more challenging to treat with immunotherapy than some other malignancies because of their variable tumour mutational burden and relative scarcity of infiltrating T cells, immune checkpoint inhibitor (ICPI) trials conducted over the last few years suggest there is an important role for these treatments. ICPI efficacy may be demonstrated in specific molecular subtypes of OG cancer. This review outlines the improvements in defining predictive biomarkers of responsiveness to ICPIs. Increasingly, identification of an expanding list of ICPI resistance mechanisms will drive biomarker-directed research. In addition, the specific rationale to combine ICPIs with chemotherapies, radiotherapies, targeted therapies and other novel immunotherapeutic drugs will be discussed.en_US
dc.format.extent1758835918786228 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectbiomarkersen_US
dc.subjectchemotherapyen_US
dc.subjectgastric canceren_US
dc.subjectimmune-checkpoint inhibitorsen_US
dc.subjectoesophageal canceren_US
dc.subjectresistanceen_US
dc.subjecttargeted therapiesen_US
dc.titleThe evolving immunotherapeutic landscape in advanced oesophagogastric cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-05-25en_US
rioxxterms.versionofrecord10.1177/1758835918786228en_US
rioxxterms.licenseref.startdate2018en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfTher Adv Med Oncolen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished onlineen_US
pubs.volume10en_US
pubs.embargo.termsNot knownen_US
icr.researchteamGastrointestinal Cancers Clinical Trialsen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden_US
dc.contributor.icrauthorStarling, Naureenen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/